Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation

Journal of Immunology

Volumn 179, Issue 7, 2007, Pages 4451-4463

  Wang, Hao ^a,b   Arp, Jacqueline ^b   Liu, Weihua ^b   Faas, Susan J ^c   Jiang, Jifu ^b   Gies, David R ^c   Ramcharran, Siobhan ^b   Garcia, Bertha ^b   Zhong, Robert ^a,b   Rother, Russell P ^c  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c ALEXION PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY MEDIATED REJECTION; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; DRUG INHIBITION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART GRAFT; HEART TRANSPLANTATION; HISTOPATHOLOGY; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SKIN GRAFT; THROMBOSIS;

ANIMALS; ANTIBODIES; COMPLEMENT SYSTEM PROTEINS; CYCLOPHOSPHAMIDE; CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; MALE; MICE; NECROSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 40649099165     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.7.4451     Document Type: Article

References (70)

1. Glotz, D., C. Antoine, P. Julia, C. Suberbielle-Boissel, S. Boudjeltia, R. Fraoui, C. Hacen, A. Duboust, and J. Bariety. 2002. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am. J. Transplant. 2: 758-760.
2. Kupiec-Weglinski, J. W. 1996. Graft rejection in sensitized recipients. Ann. Transplant. 1: 34-40.
3. Kissmeyer-Nielsen, F., S. Olsen, V. P. Petersen, and O. Fjeldborg. 1966. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 2: 662-665.
4. Williams, G. M., D. M. Hume, R. P. Hudson, Jr., P. J. Morris, K. Kano, and F. Milgrom. 1968. "Hyperacute" renal-homograft rejection in man. N. Engl. J. Med. 279: 611-618.
5. Snanoudj, R., S. Beaudreuil, N. Arzouk, H. de Preneuf, A. Durrbach, and B. Charpentier. 2005. Immunological strategies targeting B cells in organ grafting. Transplantation 79: S33-S36.
6. Crespo, M., M. Pascual, N. Tolkoff-Rubin, S. Mauiyyedi, A. B. Collins, D. Fitzpatrick, M. L. Farrell, W. W. Williams, F. L. Delmonico, A. B. Cosimi, et al. 2001. Acute humoral rejection in renal allograft recipients. I. Incidence, serology and clinical characteristics. Transplantation 71: 652-658.
7. Palmer, A., D. Taube, K. Welsh, M. Bewick, P. Gjorstrup, and M. Thick. 1989. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1: 10-12.
8. Ross, C. N., G. Gaskin, S. Gregor-Macgregor, A. A. Patel, N. J. Davey, R. I. Lechler, G. Williams, A. J. Rees, and C. D. Pusey. 1993. Renal transplantation following immunoadsorption in highly sensitized recipients. Transplantation 55: 785-789.
9. Kriaa, F., Y. Laurian, C. Hiesse, G. Tchernia, and B. Charpentier. 1995. Five years' experience at one centre with protein A immunoadsorption in patients with deleterious allo/autoantibodies (anti-HLA antibodies, autoimmune bleeding disorders) and post-transplant patients relapsing with focal glomerular sclerosis. Nephrol. Dial. Transplant. 10(Suppl. 6): 108-110.
10. Sonnenday, C. J., L. E. Ratner, A. A. Zachary, J. F. Burdick, M. D. Samaniego, E. Kraus, D. S. Warren, and R. A. Montgomery. 2002. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant. Proc. 34: 1614-1616.
11. Rocha, P. N., D. W. Butterly, A. Greenberg, D. N. Reddan, J. Tuttle-Newhall, B. H. Collins, P. C. Kuo, N. Reinsmoen, T. Fields, D. N. Howell, and S. R. Smith. 2003. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 75: 1490-1495.
12. Takemoto, S. K., A. Zeevi, S. Feng, R. B. Colvin, S. Jordan, J. Kobashigawa, J. Kupiec-Weglinski, A. Matas, R. A. Montgomery, P. Nickerson, et al. 2004. National conference to assess antibody-mediated rejection in solid organ transplantation. Am. J. Transplant. 4: 1033-1041.
13. Takeda, A., K. Uchida, T. Haba, Y. Tominaga, A. Katayama, T. Kobayashi, T. Oikawa, and K. Morozumi. 2000. Acute humoral rejection of kidney allografts in patients with a positive flow cytometry crossmatch (FCXM). Clin. Transplant. 14(Suppl. 3): 15-20.
14. Hakim, R. M., E. Milford, J. Himmelfarb, R. Wingard, J. M. Lazarus, and R. M. Watt. 1990. Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am. J. Kidney Dis. 16: 423-431.
15. Glotz, D., J. P. Haymann, N. Sansonetti, A. Francois, V. Menoyo-Calonge, J. Bariety, and P. Druet. 1993. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg): a potential tool for transplantation of immunized patients. Transplantation 56: 335-337.
16. Tyan, D. B., V. A. Li, L. Czer, A. Trento, and S. C. Jordan. 1994. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 57: 553-562.
17. Frank, M. M., and L. F. Fries. 1991. The role of complement in inflammation and phagocytosis. Immunol. Today 12: 322-326.
18. Tomlinson, S. 1993. Complement defense mechanisms. Curr. Opin. Immunol. 5: 83-89.
19. Nielsen, C. H., E. M. Fischer, and R. G. Leslie. 2000. The role of complement in the acquired immune response. Immunology 100: 4-12.
20. Carroll, M. C. 1998. The role of complement and complement receptors in induction and regulation of immunity. Annu. Rev. Immunol. 16: 545-568.
21. Arvieux, J., H. Yssel, and M. G. Colomb. 1988. Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones. Immunology 65: 229-235.
22. Dempsey, P. W., M. E. Allison, S. Akkaraju, C. C. Goodnow, and D. T. Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271: 348-350.
23. Jacquier-Sarlin, M. R., F. M. Gabert, M. B. Villiers, and M. G. Colomb. 1995. Modulation of antigen processing and presentation by covalently linked complement C3b fragment. Immunology 84: 164-170.
24. Platt, J. L., and S. Saadi. 1999. The role of complement in transplantation. Mol. Immunol. 36: 965-971.
25. Baldwin, W. M., 3rd, C. P. Larsen, and R. L. Fairchild. 2001. Innate immune responses to transplants: a significant variable with cadaver donors. Immunity 14: 369-376.
26. Halloran, P. F. 2003. The clinical importance of alloantibody-mediated rejection. Am. J. Transplant. 3: 639-640.
27. Collins, A. B., E. E. Schneeberger, M. A. Pascual, S. L. Saidman, W. W. Williams, N. Tolkoff-Rubin, A. B. Cosimi, and R. B. Colvin. 1999. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. 10: 2208-2214.
28. Pratt, J. R., M. J. Hibbs, A. J. Laver, R. A. Smith, and S. H. Sacks. 1996. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am. J. Pathol. 149: 2055-2066.
29. Pruitt, S. K., and R. R. Bollinger. 1991. The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J. Surg. Res. 50: 350-355.
30. Forbes, R. D., M. Pinto-Blonde, and R. D. Guttmann. 1978. The effect of anticomplementary cobra venom factor on hyperacute rat cardiac allograft rejection. Lab. Invest. 39: 463-470.
31. Pratt, J. R., K. Abe, M. Miyazaki, W. Zhou, and S. H. Sacks. 2000. In situ localization of C3 synthesis in experimental acute renal allograft rejection. Am. J. Pathol. 157: 825-831.
32. Brauer, R. B., W. M. Baldwin, 3rd, S. Ibrahim, and F. Sanfilippo. 1995. The contribution of terminal complement components to acute and hyperacute allograft rejection in the rat. Transplantation 59: 288-293.
33. Miyatake, T., K. Sato, K. Takigami, N. Koyamada, W. W. Hancock, H. Bazin, D. Latinne, F. H. Bach, and M. P. Soares. 1998. Complement-fixing elicited antibodies are a major component in the pathogenesis of xenograft rejection. J. Immunol. 160: 4114-4123.
34. Bach, F. H., C. Ferran, P. Hechenleitner, W. Mark, N. Koyamada, T. Miyatake, H. Winkler, A. Badrichani, D. Candinas, and W. W. Hancock. 1997. Accommodation of vascularized xenografts: expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nat. Med. 3: 196-204.
35. Park, W. D., J. P. Grande, D. Ninova, K. A. Nath, J. L. Platt, J. M. Gloor, and M. D. Stegall. 2003. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am. J. Transplant. 3: 952-960.
36. L and alloantibody. Am. J. Transplant. 1: 260-269.
37. Warren, D. S., A. A. Zachary, C. J. Sonnenday, K. E. King, M. Cooper, L. E. Ratner, R. S. Shirey, M. Haas, M. S. Leffell, and R. A. Montgomery. 2004. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am. J. Transplant. 4: 561-568.
38. Jose, P. J., M. J. Forrest, and T. J. Williams. 1983. Detection of the complement fragment C5a in inflammatory exudates from the rabbit peritoneal cavity using radioimmunoassay. J. Exp. Med. 158: 2177-2182.
39. Kirschfink, M. 2001. Targeting complement in therapy. Immunol. Rev. 180: 177-189.
40. Saadi, S., R. A. Holzknecht, C. P. Patte, D. M. Stern, and J. L. Platt. 1995. Complement-mediated regulation of tissue factor activity in endothelium. J. Exp. Med. 182: 1807-1814.
41. Papadimitriou, J. C., L. E. Ramm, C. B. Drachenberg, B. F. Trump, and M. L. Shin. 1991. Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9. J. Immunol. 147: 212-217.
42. Liszewski, K. M. 1993. In Fundamental Immunology. W. E. Paul, ed. Raven, New York, pp. 917-939.
43. Wang, H., J. Jiang, W. Liu, D. Kubelik, G. Chen, D. Gies, B. Garcia, R. Zhong, and R. P. Rother. 2005. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation 79: 1121-1127.
44. Olfert, E. D., B. M. Cross, and A. A. McWilliam. 1993. Responsibility for the care and use of experimental animals. In Guide to the Care and Use of Experimental Animals, Vol. 1. E. D. Olfert, B. M. Cross, and A. A. McWilliam, eds. Association of Universities and Colleges of Canada, Ottawa, pp. 1-14.
45. Wang, H., K. A. Hosiawa, W. Min, J. Yang, X. Zhang, B. Garcia, T. E. Ichim, D. Zhou, D. Lian, D. J. Kelvin, and R. Zhong. 2003. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J. Immunol. 171: 3823-3836.
46. Wang, H., S. A. Rollins, Z. Gao, B. Garcia, Z. Zhang, J. Xing, L. Li, R. Kellersmann, L. A. Matis, and R. Zhong. 1999. Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model. Transplantation 68: 1643-1651.
47. Kobayashi, Y. M., and L. R. Jones. 1999. Identification of triadin 1 as the predominant triadin isoform expressed in mammalian myocardium. J. Biol. Chem. 274: 28660-28668.
48. Arp, J., M. LeVatte, J. Rowe, S. Perkins, E. King, C. Leystra-Lantz, S. K. Foung, and G. A. Dekaban. 1996. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system. J. Virol. 70: 7349-7359.
49. Mohiuddin, M. M., H. Ogawa, D. P. Yin, J. Shen, and U. Galili. 2003. Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen. Transplantation 75: 258-262.
50. Koch, C. A., Z. I. Khalpey, and J. L. Platt. 2004. Accommodation: preventing injury in transplantation and disease. J. Immunol. 172: 5143-5148.
51. Colvin, R. B., and R. N. Smith. 2005. Antibody-mediated organ-allograft rejection. Nat. Rev. Immunol. 5: 807-817.
52. Montgomery, R. A., A. A. Zachary, L. C. Racusen, M. S. Leffell, K. E. King, J. Burdick, W. R. Maley, and L. E. Ratner. 2000. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70: 887-895.
53. Konteatis, Z. D., S. J. Siciliano, G. Van Riper, C. J. Molineaux, S. Pandya, P. Fischer, H. Rosen, R. A. Mumford, and M. S. Springer. 1994. Development of C5a receptor antagonists: differential loss of functional responses. J. Immunol. 153: 4200-4205.
54. Nicholson-Weller, A., and J. A. Halperin. 1993. Membrane signaling by complement C5b-9, the membrane attack complex. Immunol. Res. 12: 244-257.
55. Arumugam, T. V., I. A. Shiels, T. M. Woodruff, R. C. Reid, D. P. Fairlie, and S. M. Taylor. 2002. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J. Surg. Res. 103: 260-267.
56. Haynes, D. R., D. G. Harkin, L. P. Bignold, M. J. Hutchens, S. M. Taylor, and D. P. Fairlie. 2000. Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist. Biochem. Pharmacol. 60: 729-733.
57. Kroshus, T. J., S. A. Rollins, A. P. Dalmasso, E. A. Elliott, L. A. Matis, S. P. Squinto, and R. M. Bolman, 3rd. 1995. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 60: 1194-1202.
58. Baldwin, W. M., 3rd, S. K. Pruitt, R. B. Brauer, M. R. Daha, and F. Sanfilippo. 1995. Complement in organ transplantation: contributions to inflammation, injury, and rejection. Transplantation 59: 797-808.
59. Sims, P. J., and T. Wiedmer. 1991. The response of human platelets to activated components of the complement system. Immunol. Today 12: 338-342.
60. Weyrich, A. S., M. R. Elstad, R. P. McEver, T. M. McIntyre, K. L. Moore, J. H. Morrissey, S. M. Prescott, and G. A. Zimmerman. 1996. Activated platelets signal chemokine synthesis by human monocytes. J. Clin. Invest. 97: 1525-1534.
61. Kilgore, K. S., C. M. Flory, B. F. Miller, V. M. Evans, and J. S. Warren. 1996. The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am. J. Pathol. 149: 953-961.
62. Whittum, J. A., and R. R. Lindquist. 1977. Mechanisms of cardiac allograft rejection in the inbred rat: the effect of complement depletion by cobra venom factor on hyperacute cardiac allograft rejection. Transplantation 24: 226-228.
63. Pruitt, S. K., A. D. Kirk, R. R. Bollinger, H. C. Marsh, Jr., B. H. Collins, J. L. Levin, J. R. Mault, J. S. Heinle, S. Ibrahim, A. R. Rudolph, et al. 1994. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 57: 363-370.
64. Hammerberg, C., S. K. Katiyar, M. C. Carroll, and K. D. Cooper. 1998. Activated complement component 3 (C3) is required for ultraviolet induction of immunosuppression and antigenic tolerance. J. Exp. Med. 187: 1133-1138.
65. Sohn, J. H., P. S. Bora, H. J. Suk, H. Molina, H. J. Kaplan, and N. S. Bora. 2003. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat. Med. 9: 206-212.
66. Kawamoto, S., A. Yalcindag, D. Laouini, S. Brodeur, P. Bryce, B. Lu, A. A. Humbles, H. Oettgen, C. Gerard, and R. S. Geha. 2004. The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen. J. Clin. Invest. 114: 399-407.
67. Hawlisch, H., Y. Belkaid, R. Baelder, D. Hildeman, C. Gerard, and J. Kohl. 2005. C5a negatively regulates Toll-like receptor 4-induced immune responses. Immunity 22: 415-426.
68. Bach, F. H., W. W. Hancock, and C. Ferran. 1997. Protective genes expressed in endothelial cells: a regulatory response to injury. Immunol. Today 18: 483-486.
69. Schwartz, R. S. 2004. Black mornings, yellow sunsets-a day with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350: 537-538.
70. Hill, A., P. Hillmen, S. J. Richards, D. Elebute, J. C. Marsh, J. Chan, C. F. Mojcik, and R. P. Rother. 2005. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 106: 2559-2565.